Renfeng Shan

473 citations
27 papers · 297 indexed · h-index 12
Topics
Hepatocellular Carcinoma Treatment and Prognosis (10 papers)MicroRNA in disease regulation (7 papers)Circular RNAs in diseases (6 papers)
Journals
SHILAP Revista de lepidopterologíaInternational Journal of CancerJournal of Cellular Physiology
Partner nations
ChinaCanada

In The Last Decade

Renfeng Shan

25 papers receiving 295 citations

Peers

Renfeng Shan
Comparison fields: 5 of 48
  • Molecular Biology 122
  • Cancer Research 116
  • Hepatology 90
  • Oncology 76
  • Surgery 68
Replace Zhong-Guo Zhou with:
Zhong-Guo Zhou China
Nicolai Aagaard Schultz Denmark
Masaharu Kogure Japan
G. Maddalo Italy
Ting‐Jung Wu Taiwan
Burcin Özdirik Germany
Quan Xu China
Helen Bolanaki Greece
Pengsheng Yi China
Jean Philippe Metges France
Renfeng Shan relative to Zhong-Guo Zhou China Zhong-Guo Zhou's profile →
Citations per field
00.5×4.1×
Zhong-Guo Zhou · 1×
Citations per year

Countries citing papers authored by Renfeng Shan

Since Specialization
Citations

This map shows the geographic impact of Renfeng Shan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Renfeng Shan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Renfeng Shan more than expected).

Fields of papers citing papers by Renfeng Shan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Renfeng Shan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Renfeng Shan. The network helps show where Renfeng Shan may publish in the future.

Co-authorship network of co-authors of Renfeng Shan

This figure shows the co-authorship network connecting the top 25 collaborators of Renfeng Shan. A scholar is included among the top collaborators of Renfeng Shan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Renfeng Shan. Renfeng Shan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 4
2 5
3 4
4 2
5 0
6 10
7 13
8 10
9 0
10 23
11 4
12 26
13 20
14 12
15 13
16 27
17 8
18 15
19 4
20 12

About Renfeng Shan

Renfeng Shan is a scholar working on Hepatology, Cancer Research and Oncology, having authored 27 papers that have together received 297 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (10 papers), MicroRNA in disease regulation (7 papers) and Circular RNAs in diseases (6 papers). The work is most often cited by research in Hepatology (90 citations), Cancer Research (116 citations) and Oncology (76 citations). Renfeng Shan has collaborated with scholars based in China and Canada. Frequent co-authors include Jianfeng Li, Hua Qiu, Zhigao Hu, Jin Xie, Mengxi Xiu, Wei Deng, Jinfeng Tan, Tao Wang, Daya Luo and Lianghui Gao. Their work appears in journals such as SHILAP Revista de lepidopterología, International Journal of Cancer and Journal of Cellular Physiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026